MURAライブシグナル | Getagraph.comで利益を最大化

買う 151735 min ago

@ $4.55

発行日: 15 2月 2024 @ 02:08

リターン: -26.37%

前回のシグナル: 2月 14 - 23:34

前回のシグナル: 売る

リターン: -0.44 %

Live Chart Being Loaded With Signals

Commentary (30 5月 2024 @ 05:00):

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer...

Stats
本日の出来高	174 099
平均出来高	187 395
時価総額	56.69M
EPS	$0 ( 2024-03-14 )
次の収益日	( $-2.66 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0100 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Cuss Francis M	Buy	15 021	Stock Option (right to buy)
2023-12-14	Jackson Scott Thomas	Buy	15 021	Stock Option (right to buy)
2023-12-14	Hickey Benjamin	Buy	15 021	Stock Option (right to buy)
2023-12-14	Cutler Adam D.	Buy	146 452	Stock Option (right to buy)
2023-12-14	Cutler Adam D.	Buy	78 859	Ordinary Shares

INSIDER POWER
100.00
Last 10 transactions
Buy: 353 823 \| Sell: 0

ボリューム相関

長: -0.41 (neutral)

短: 0.08 (neutral)

Signal:(54.386) Neutral

Mural Oncology plc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Mural Oncology plc 相関 - 通貨/商品

0.06
( neutral )

-0.19
( neutral )

0.00
( neutral )

0.58
( weak )

-0.59
( weak negative )

Mural Oncology plc 財務諸表

Annual	2023
収益:	$0
総利益:	$-2.57M (0.00 %)
EPS:	$-12.43

FY	2023
収益:	$0
総利益:	$-2.57M (0.00 %)
EPS:	$-12.43

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-11.99

Financial Reports:

No articles found.

Mural Oncology plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Mural Oncology plc

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company\'s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.